Paper Details

  1. Home
  2. Paper Details

Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

Author: MoeSoe, MyintKay Thi, NiHan, SoeZay, ViswanathanK Neelakantan

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

The study reviews the use of long-acting beta<sub>2</sub>-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combinations in treating stable chronic obstructive pulmonary disease (COPD). It focuses on the fixed-dose combination (FDC) of aclidinium/formoterol, one of the approved LABA/LAMA therapies for COPD.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Several dual bronchodilator combinations of long-acting beta<sub>2</sub>-agonist (LABA) and long-acting muscarinic antagonist (LAMA) have been approved for treatment of stable chronic obstructive pulmonary disease (COPD). The current GOLD (Global Initiativ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517126/

データ提供：米国国立医学図書館（NLM）

Combined Aclidinium Bromide and Long-Acting Beta2-agonist: A New Approach for COPD

Chronic obstructive pulmonary disease (COPD), a debilitating respiratory condition, can be likened to a desert wind that slowly erodes the lungs, making it difficult to breathe. This research explores the potential benefits of combining aclidinium bromide, a long-acting muscarinic antagonist (LAMA), with a long-acting beta2-agonist (LABA) for the treatment of COPD. The study highlights the current GOLD recommendations for the use of LABA/LAMA combinations in patients with COPD, focusing on the fixed-dose combination of aclidinium/formoterol.

Dual Bronchodilator Therapy: A Promising Approach for COPD

This research, like a desert oasis offering relief from the scorching sun, explores a new strategy for treating COPD. The study's focus on the combination of aclidinium bromide and a long-acting beta2-agonist suggests a potential for improved bronchodilation and symptom management in patients with COPD. The research underscores the importance of tailored treatment approaches based on individual patient needs and disease severity, as outlined in the GOLD recommendations.

Navigating the Complexities of COPD Treatment

This study, like a map through a challenging desert landscape, offers valuable insights into the treatment of COPD. The study's focus on dual bronchodilator therapy, specifically the combination of aclidinium bromide and a long-acting beta2-agonist, highlights the potential for improved symptom management and overall quality of life for patients with COPD.

Dr. Camel's Conclusion

This research, like a refreshing spring in the desert of COPD treatment, explores a promising new approach for managing this debilitating respiratory condition. The study's focus on dual bronchodilator therapy, specifically the combination of aclidinium bromide and a long-acting beta2-agonist, suggests a potential for improved bronchodilation and symptom management in patients with COPD.
Date :
  1. Date Completed 2019-03-06
  2. Date Revised 2022-08-30
Further Info :

Pubmed ID

30536566

DOI: Digital Object Identifier

PMC6517126

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.